Viatris Inc. is expected to report Q2 2026 revenue of $3.66 billion and EPS of $0.62 on August 06, 2026, with the current stock price of $17.63 trading slightly above the $17.50 average analyst target.
Investors are primarily focused on the performance of the Developed Markets segment, which analysts estimate will generate $2.18 billion in revenue for the quarter.
Supporting this focus is the ongoing impact of the FDA import alert on the company's Indore manufacturing facility, which has hampered North American distribution for key legacy products. However, sentiment has been bolstered by recent regulatory progress, including the U.S. FDA approval of the Gwyn Lo contraceptive patch and positive Phase 3 clinical results for IgA nephropathy in Japan.